Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Goldman Sachs Maintains Neutral on Centessa Pharmaceuticals, Lowers Price Target to $4

Goldman Sachs Maintains Neutral on Centessa Pharmaceuticals, Lowers Price Target to $4

Goldman Sachs analyst Salveen Richter maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Neutral and lowers the price target from $5 to $4.

byBenzinga Newsdesk

August 11, 2022

1 minute read

Goldman Sachs analyst Salveen Richter maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Neutral and lowers the price target from $5 to $4.

Novo Nordisk Once-Weekly Insulin Hits Primary Goals In In Two Phase 3 Trials

By Vandana Singh

July 29, 1:42 PM

Novo Nordisk A/S (NYSE:NVO) announced headline results from the ONWARDS 3 and ONWARDS 4 Phase 3a trials with once-weekly insulin icodec…

NVO

Key Apple Hire Departs Microsoft’s AI And Mixed Reality Division, Report Says

By Benzinga Neuro

February 7, 8:49 AM

Caballero, who previously served as Apple's president of engineering, was hired by Microsoft to work on devices such as HoloLens in the company's mixed reality and AI organization.

AAPL

Qorvo Analysts Cut Their Forecasts After Weak Outlook

By Avi Kapoor

May 2, 9:05 AM

Qorvo, Inc. (NASDAQ:QRVO) reported upbeat results for the fourth quarter, but issued weak current-quarter forecast. Qorvo posted adjusted…

QRVO

AstraZeneca Inks Over $2B Agreement For Cell Therapies Targeting Diabetes

By Vandana Singh

June 9, 8:14 AM

AstraZeneca plc (NASDAQ: AZN) has entered into a

AZN

Goldman Sachs Maintains Neutral on Centessa Pharmaceuticals, Lowers Price Target to $4

Related Posts

Novo Nordisk Once-Weekly Insulin Hits Primary Goals In In Two Phase 3 Trials

Key Apple Hire Departs Microsoft’s AI And Mixed Reality Division, Report Says

Qorvo Analysts Cut Their Forecasts After Weak Outlook

AstraZeneca Inks Over $2B Agreement For Cell Therapies Targeting Diabetes